Salute e Benessere

Zealand Pharma completes registration of capital increase

Company announcement – No. 36 / 2024 Zealand Pharma completes registration of capital increaseNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY SECURITIES IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT...

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of…

Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ®NHL-1 studyFL is the second most common type of NHL and accounts for approximately 20-30 percent of all global casesIf approved, epcoritamab (TEPKINLY ® ) would become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after...

Gerresheimer: New pictures available

Media Contact Media Contact Jutta LorbergHead of Corporate CommunicationT +49 211 6181 264jutta.lorberg@gerresheimer.com View original content: https://www.prnewswire.co.uk/news-releases/gerresheimer-new-pictures-available-302184778.html

Hansa Biopharma: increase in number of shares and votes

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST. This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through...

BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATIONMont-Saint-Guibert, Belgium, June 28, 2024, 7.00 am CET –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication...

Natalia Vodianova Invests in Swiss Beauty and Longevity Brand NIANCE

NIANCE is a Zurich-based luxury skincare and nutritional supplement brand, Switzerland's best-kept secret in beauty and longevity. Celebrated for its groundbreaking biotechnology, FERNESSE™, this technology enables the release of the full Triple-Biotic power (prebiotics, probiotics, and postbiotics) of its active ingredients, significantly increasing the bioavailability of nutrients. By addressing the root cause of aging, NIANCE combines the finest natural ingredients from the Swiss Alps with…

Dioseve Completes Funding Round, Raising a Total of 7 Million USD

*1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd. *1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd. *2. The Common name for the "Hokuriku Regional Venture Investment Limited Partnership," co-managed by QR Investment Inc. (a subsidiary of Hokugin…

Leqembi® (lecanemab) launched in China

In China, Leqembi will first be launched in the private market and the price for a 200 mg vial will be CNY 2,508. In collaboration with Eisai, a major Chinese medical insurance company has developed and launched a healthcare insurance plan specifically for AD including partial coverage of the drug cost. Through these efforts, Eisai is committed to promoting the early detection, diagnosis, and treatment of AD in China. InChina, Leqembi will first be launched in the private market and the...

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer's Disease Launched in…

China is the Third Country to Launch LEQEMBI Following the United States and Japan TOKYO and CAMBRIDGE, Mass., June27, 2024(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI ® ” (brand name in China: “乐意保 ® ”, generic name:...

Systemic Sclerosis Market to Exhibit Significant Growth by 2034, Predicts…

Key Takeaways from the Systemic Sclerosis Market Report Key Takeaways from the Systemic Sclerosis Market Report Discover which therapies are expected to grab the major systemic sclerosis market share @Systemic Sclerosis Market Report Systemic Sclerosis Overview Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. The condition arises due to the overproduction and...

Completion of Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 27, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2024. On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program was expected to be completed no later than December 16, 2024.The following transactions were executed under the program from June 24, 2024, to June 26, 2024: ...

Inside Information: Update for Bioretec's RemeOs™ Trauma Screw European…

Further enquiries Further enquiries Alan Donze, CEO, tel. +358 40 663 5011 Johanna Salko, CFO, tel. +358 40 754 8172 Certified advisor Nordic Certified Adviser AB, +46 70 551 67 29 Bioretec in brief Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate...

American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech…

The article continued: According to the World Health Organization, the global cancer burden is growing amidst a mounting need for services. As well, an alarming trend is emerging, where cancer cases in younger people are rising sharply. The article continued: According to theWorld Health Organization, theglobal cancer burden is growing amidst a mounting need for services. As well, analarming trend is emerging, where cancer cases in younger people are rising sharply. Oncolytics...

Nicox: 2024 Ordinary Shareholder Meeting

Press ReleaseNicox: 2024 Ordinary Shareholder MeetingJune 27, 2024 – release at 17:30 CETSophia Antipolis, France Nicox SA(Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary general meeting convened on first call on Friday June 28, 2024, will not be held as the quorum required by law has not been reached.The shareholders of Nicox are thus convened on second call for an Ordinary general meeting on the...

New Board of RADAS, UAB

Additional Information MAXIMA GRUPĖ, UAB manages retail chains "Maxima" (in the Baltic countries), "Stokrotka" (in Poland), "T Market" (in Bulgaria), and the online food store "Barbora," operating in the Baltic countries. MAXIMA GRUPĖ, UAB is part of the "Vilniaus prekyba" group of companies. Through its other subsidiary companies, "Vilniaus prekyba" controls investments in retail and pharmacy chains, as well as real estate development…

IoT in Healthcare Market: Digitization Surge to Propel Valuation Beyond $926.9B…

Download a detailed overview:https://www.skyquestt.com/sample-request/iot-in-healthcare-market Download a detailed overview: https://www.skyquestt.com/sample-request/iot-in-healthcare-market IoT In Healthcare Market Overview: Segments covered in IoT in Healthcare Market are as follows: Request Free Customization of this report: https://www.skyquestt.com/speak-with-analyst/iot-in-healthcare-market Hospitals to Remain at the Top in Terms of IoT in Healthcare Adoption...

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted…

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany,...

Next-generation Sequencing Services Market to be Worth $24.44 billion by 2031 -…

The growth of this market is mainly attributed to the reduced cost of NGS procedures, the development and approval of new targeted therapies, the rising prevalence of cancer, partnerships between NGS service providers and pharmaceutical companies, the high cost of sequencing infrastructure, and technological advancements in NGS. In addition, advancements in sequencing data analytics and the increasing applications of NGS in cancer and agri-genomics research are expected to offer significant…

Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to…

Company Announcement, Helsinki, 27 June 2024 at 4:45 PM (EEST) Nexstim Plc Has Agreed on a Digitalization and Innovation Loan with Finnvera to Finance Product Development Project Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on an EUR 1.5 million digitalization and innovation loan with Finnvera. The loan has been implemented in cooperation with the European Investment Fund. The Company intends to use the loan for financing product development work of its NBS 6…

KFSH&RC Leads Global Healthcare Revolution with AI and Robotics

RIYADH, Saudi Arabia, June27, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) is at the forefront of the global AI and robotics revolution. These technological advancements, driven by Saudi Vision 2030, are set to unlock an estimated $15 billion to $27 billion in economic value for the Kingdom's medical sector by 2030, in addition to their pivotal role in streamlining processes and transforming patient care.Robotic-assisted surgeries are a...

Kameleoon Partners with North America's Largest Experimentation Event to Launch…

EXL+UNITE combines conference elements with networking, making it a premier destination for experimentation experts, product innovators, and growth leaders. The event fosters deep connections and shares practitioner-only knowledge. EXL+UNITE combines conference elements with networking, making it a premier destination for experimentation experts, product innovators, and growth leaders. The event fosters deep connections and shares practitioner-only knowledge. Event Highlights ...

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

®Index and the broad-market Russell 3000 ®Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. “We are pleased to be joining the Russell 2000 ®Index,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. “This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones...

Crown Laboratories, Inc. and BIOJUVE® Celebrate World Microbiome Day 2024

Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9271351-crown-laboratories-biojuve-celebrate-world-microbiome-day/ Experience the full interactive Multichannel News Release here:https://www.multivu.com/players/English/9271351-crown-laboratories-biojuve-celebrate-world-microbiome-day/ Genetics, stress, environmental factors, age, pathogens and more can create an imbalance in the skin's natural microbiome, but consumers can help...

STALICLA publishes pioneering phase 1b data on precision treatment for autism…

Press ReleaseSTALICLA's precision psychiatry study highlights strong EEG-based target engagement of STP1 treatment in defined subgroup of patients with autism and numerical improvement in core symptomsGeneva, Switzerland – June 27, 2024– STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neuropsychiatric and neurodevelopmental disorders, today announced the publication of a landmark phase 1b study with STP1, a novel...

Altri Comunicati